All In Biotech

Drug Trial Radar · NCT07174427

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Mar 2032

Study completion Mar 2032

Sponsor

Lead sponsor
Takara Bio Inc.Industry
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.

Conditions

  • Synovial Sarcomas

Interventions

  • TBI-1301Biological

    Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.

  • CyclophosphamideDrug

    Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

  • FludarabineDrug

    Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: 52 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Kyusyu University Hospital

    Fukuoka, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.